Viatris Inc. - Common Stock (NQ:VTRS)

19.12 -0.07 (-0.39%)

Delayed Quote Updated: 11:31 AM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

What's going on in today's session: S&P500 gap up and gap down stocks ↗

May 07, 2026

Via Chartmill

Viatris (NASDAQ:VTRS) Shares Rise as Q1 Earnings Top Estimates ↗

May 07, 2026

Via Chartmill

Viatris’s (NASDAQ:VTRS) Q1 CY2026: Beats On Revenue

May 07, 2026

Medication company Viatris (NASDAQ:VTRS) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 8.1% year on year to $3.52 bil...

Via StockStory

Topics Artificial Intelligence

Earnings To Watch: Viatris (VTRS) Reports Q1 Results Tomorrow

May 05, 2026

Medication company Viatris (NASDAQ:VTRS) will be announcing earnings results this Thursday before the bell. Here’s what investors should know. Viatris beat a...

Via StockStory

Topics Artificial Intelligence

Natera, UFP Technologies, Mettler-Toledo, and Viatris Shares Are Soaring, What You Need To Know

April 17, 2026

What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener...

Via StockStory

Topics Economy Government Stocks

Viatris Inc (NASDAQ:VTRS) Beats Q4 2025 Estimates and Completes Strategic Review ↗

February 26, 2026

Via Chartmill

QSM Asset Management Loads Up 611,000 Mobileye Shares ↗

April 16, 2026

Mobileye develops advanced driver assistance and autonomous driving technologies for global automotive manufacturers and suppliers.

Via The Motley Fool

Topics Economy Regulatory Compliance Supply Chain

A Fund Just Bet $5.7 Million on Robert Half -- Is the Staffing Sector Due for a Rebound? ↗

April 15, 2026

Robert Half Inc. provides staffing and risk consulting solutions globally to employers across diverse industries.

Via The Motley Fool

Topics Regulatory Compliance

QSM Asset Management Bets on Beaten-Down Manpower Group With New $5.9 Million Stake in ManpowerGroup ↗

April 15, 2026

ManpowerGroup provides staffing and HR solutions worldwide, serving clients in 75 countries.

Via The Motley Fool

Topics Regulatory Compliance

What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year ↗

March 20, 2026

This medical technology firm delivers integrated blood management solutions to healthcare providers and plasma centers worldwide.

Via The Motley Fool

Topics Regulatory Compliance

1 Cash-Producing Stock to Target This Week and 2 That Underwhelm

March 17, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Via StockStory

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision ↗

March 13, 2026

Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions.

Via The Motley Fool

Topics Regulatory Compliance

Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug ↗

March 13, 2026

Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.

Via The Motley Fool

Topics Regulatory Compliance

Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline ↗

March 13, 2026

Praxis Precision Medicines develops therapies for central nervous system disorders, targeting unmet needs in neurology and psychiatry.

Via The Motley Fool

Viatris (VTRS): Buy, Sell, or Hold Post Q4 Earnings?

March 10, 2026

Viatris has had an impressive run over the past six months as its shares have beaten the S&P 500 by 34.7%. The stock now trades at $14.11, marking a 37.8% ga...

Via StockStory

Topics Stocks

Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive

March 03, 2026

As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent...

Via Finterra

Topics Economy Initial Public Offering Retirement

Spotting Winners: Viatris (NASDAQ:VTRS) And Generic Pharmaceuticals Stocks In Q4

March 02, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceu...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Bastion Bets on Government Spending with $8 Million New Stake in Parsons ↗

February 27, 2026

Parsons delivers technology-driven solutions for defense, intelligence, and critical infrastructure clients across North America and beyond.

Via The Motley Fool

The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy

February 26, 2026

As of February 26, 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a defining crossroads. For years, the company was viewed by many on Wall Street as a "value trap"—a debt-laden giant formed from the...

Via Finterra

Topics Economy

Wondering what's happening in today's S&P500 pre-market session? ↗

February 26, 2026

Via Chartmill

Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q4 CY2025

February 26, 2026

Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 5% year on year to $3.7 billion. The company’s full-year revenue guidance of...

Via StockStory

Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow

February 24, 2026

Medication company Viatris (NASDAQ:VTRS) will be announcing earnings results this Thursday before market hours. Here’s what to expect.

Via StockStory

Topics World Trade

Supreme Court Strikes Down IEEPA Tariffs, Mandating Billions in Immediate Rebates

February 24, 2026

In a seismic shift for global trade and constitutional law, the Supreme Court of the United States ruled on February 20, 2026, that the executive branch lacks the authority to unilaterally impose...

Via MarketMinute

Topics Bonds Economy Government

February 22, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other...

Via StockStory

2 Value Stocks Worth Your Attention and 1 We Brush Off

February 16, 2026

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful...

Via StockStory

Viatris at a Crossroads: Transitioning from Generic Giant to Specialty Powerhouse

February 10, 2026

February 10, 2026 Introduction As of February 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a pivotal juncture. Five years after its high-profile inception, the company has shed its skin as a...

Via Finterra

Topics Economy World Trade

Why Viatris (VTRS) Stock Is Up Today

February 09, 2026

Shares of medication company Viatris (NASDAQ:VTRS) jumped 6.4% in the afternoon session after investment bank UBS upgraded the company's stock from "Neutral" to "Buy" and increased its price target.

Via StockStory

Uncover the latest developments among S&P500 stocks in today's session. ↗

February 09, 2026

Via Chartmill

Monday's pre-market session: top gainers and losers in the S&P500 index ↗

February 09, 2026

Via Chartmill

3 Unprofitable Stocks with Questionable Fundamentals

February 03, 2026

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.

Via StockStory

Topics Electric Vehicles

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.